Citius Pharmaceuticals (NASDAQ: CTXR)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Citius Pharmaceuticals (NASDAQ: CTXR) through any online brokerage.
Other companies in Citius Pharmaceuticals’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), Rani Therapeutics Hldgs (NASDAQ:RANI), Marinus Pharma (NASDAQ:MRNS), Anebulo Pharmaceuticals (NASDAQ:ANEB) and Endo International (NASDAQ:ENDP).
The latest price target for Citius Pharmaceuticals (NASDAQ: CTXR) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting CTXR to rise to within 12 months (a possible 241.88% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Citius Pharmaceuticals (NASDAQ: CTXR) is $1.17 last updated August 12, 2022, 8:00 PM UTC.
The next Citius Pharmaceuticals (CTXR) dividend date is projected to be Thursday, September 1, 2022.
Citius Pharmaceuticals’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Citius Pharmaceuticals.
Citius Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.